Welcome to our dedicated page for Vivani Medical news (Ticker: VANI), a resource for investors and traders seeking the latest updates and insights on Vivani Medical stock.
Vivani Medical Inc (VANI) is a preclinical-stage biopharmaceutical innovator developing long-term implantable drug delivery systems through its proprietary NanoPortal™ technology. This page provides authorized news updates and press releases about the company's advancements in chronic disease treatment solutions.
Investors and industry observers will find timely updates on clinical development milestones, strategic partnerships, and regulatory progress. Our curated news collection focuses on factual reporting of implantable device innovations, research collaborations, and therapeutic application developments across Vivani's Biopharm and Neuromodulation divisions.
Key content categories include updates on NanoPortal™ technology enhancements, preclinical trial results, intellectual property developments, and executive leadership announcements. All information is verified through primary sources to ensure compliance with financial disclosure standards.
Bookmark this page for direct access to Vivani Medical's official communications, presented in chronological order with clear date stamps. For comprehensive understanding of the company's technology platform, review our detailed company profile alongside these news updates.
Vivani Medical (Nasdaq: VANI) has provided a business update and first quarter 2024 financial results. The company is advancing the development of GLP-1 implants for chronic weight management and type 2 diabetes. Key highlights include the initiation of preclinical activities for NPM-115 and the expected IND submission by year-end. A $15-million stock offering in March will fund operations until the second half of 2025. Vivani reported a cash balance of $31.0 million as of March 31, 2024, a net loss of $6.0 million, and a slight reduction in R&D and administrative expenses compared to the previous year.
Vivani Medical, Inc. (Nasdaq: VANI) will present at the TIDES Conference 2024 in Boston to discuss its lead asset NPM-115 for chronic weight management and NPM-119 for type 2 diabetes. The presentation will cover the Company's NanoPortal™ platform and updates on its programs.
FAQ
What is the current stock price of Vivani Medical (VANI)?
What is the market cap of Vivani Medical (VANI)?
